

APRIL 2026

CLINICAL RESEARCH NEWSLETTER

I&A: Administrators, Managers, Coordinators & Advanced Practice Providers Meeting

June 5, 2026

In Person: Lewis Cancer and Research Pavilion
225 Candler Dr. Savannah, GA 31405

Virtual: Link (will be provided after registration)

If you are interested in attending this meeting in person, there are funds available! Please reach

out to Shantoria Brown at
sbrown@georgiacore.org

for more information

I&A WITH GASCO

Meeting Host: Georgia Society of Clinical
Oncology

When: August 20, 2026

Where: The Hotel at Avalon
Alpharetta, GA

More Information to come

Grant Extension Update

We are currently finalizing our grant extension application, due by May 1st.

This extension covers Year 11, Part B (Year 13 for our site) and will run through July 31, 2027, with an

anticipated July 1st start date for the new grant year. No impact to day-to-day operations is expected.

We anticipate receiving the Notice of Funding Opportunity for the full

application around June and will keep everyone updated as things progress.

Table of Contents

TOPIC	PAGE
Save The Dates and Grant Extension	1
Upcoming Research Meetings	2
Studies Pending Activation/Fun facts	3
Recently Opened and Activated trials	4
CCDR Studies Open and Activated	5
Test Your Knowledge Quiz/Site Recognition	6

Contact Info

Alaina Newsome;

underberga@sjchs.org

GA NCORP CCDR

Program Coordinator

APRIL 2026



CLINICAL RESEARCH NEWSLETTER

Upcoming Research Base Meetings*

Research Base	Date	Location
NRG	July 16-18, 2026	Denver, CO
SWOG	April 30-May 2, 2026	San Francisco, CA
	October 8-10, 2026	Chicago, IL
ECOG	May 5-7, 2026	Baltimore, MD
	October 20 - 22, 2026	Philadelphia, PA
URCC	September 25-27, 2026	Niagara Falls, NY
Wake Forest	October 12-14, 2026	Myrtle Beach, SC
UPCOMING ROUTINE AUDITS ¹		
ECOG	TBD FOR 2026	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

*Please contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds and audit preparation.

ECOG-ACRIN Spring Meeting

The ECOG-ACRIN Clinical Research Associates (CRA) Core Committee has limited funds available to provide travel assistance to the upcoming meeting in Baltimore, MD, Tuesday, May 5–Thursday, May 7, 2026. Four candidates will be selected to receive a travel expense reimbursement award of up to \$1000. These funds are intended to facilitate attendance to the ECOG-ACRIN meetings for CRAs with no other form of travel support. Data managers, clinical research associates or clinical research coordinators/nurses (who do their own data) are eligible to apply. Only one candidate per institution will be supported.



APRIL 2026

CLINICAL RESEARCH NEWSLETTER

TRIALS PENDING ACTIVATION

Research Base	Title
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors
	EAQ181: Randomized Controlled Trial of FoRtitude: Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors in Community Oncology Settings
	EAQ161CD: Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting
Alliance	A222302: Family Communications After Genetic Testing
SWOG	S2424CD: Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams

About 40% of all cancers are preventable through lifestyle changes such as not smoking, maintaining a healthy weight, and limiting alcohol.

Cancer research is advancing rapidly. Immunotherapy, targeted therapy, and precision medicine are transforming how many cancers are treated today.

1 in 2 men and 1 in 3 women in the U.S. will be diagnosed with cancer at some point in their lifetime.

APRIL 2026



CLINICAL RESEARCH NEWSLETTER

Recently Activated and Recommended Trials¹

Research Base	Title	CTSU Activation Date
SWOG	LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	10/22/2025
	S2433: Randomized Phase III Study of Second-Line Chemotherapy with or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma	12/26/2025
ECOG	EA1241: Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol	12/4/2025
	EA6232: Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients with Multiple Atypical Nevi and a Prior History of Melanoma	2/20/2026
NRG	NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer	1/12/2026
	NRG-CC017: A Randomized Phase III Study Comparing Temporally-Modulated Pulsed Radiation Therapy (TMPRT) Versus Standard Radiation Therapy with Temozolomide for Adults with Newly Diagnosed MGMT-Unmethylated Glioblastoma	4/1/2026
	NRG-HN015: A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)	1/12/2026
Alliance	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
	A032304: Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL)	12/23/2025
	A212101: Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer	3/5/2026
Wake Forest	WF-2501CD: Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)	12/02/2025
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025



APRIL 2026

CLINICAL RESEARCH NEWSLETTER

ALL OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS¹

Research Base	Title	CTSU Activation Date
Alliance	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/26/2025
	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
ECOG-ACRIN	EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP) Deemed high priority by the Executive Committee.	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) Sites must receive approval prior to initiating any study start-up activities.	2/29/2024
SWOG	S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	8/4/2025
Wake Forest	WF-1805CD: Implementation and Effectiveness Trial of HN-STAR Participant enrollment closed as of 2/13/2025, but practice (non-patient) enrollment is now ongoing.	8/10/2020
	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers ² Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/23/2024
	WF-2402CD: Collaborative Oncology between Radiologists and Radiation Oncologists for the Evaluation of Contoured Targets (CORRECT)	2/20/2026
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025

APRIL 2026

CLINICAL RESEARCH NEWSLETTER

TEST OF YOUR KNOWLEDGE QUIZ!

The first person to answer correctly will receive Georgia NCORP swag and a shout-out in the next issue! Send your responses to kdixon@georgiacore.org.

1. Which of the following best describes 'intention-to-treat' (ITT) analysis?

- A. Analysis including only patients who completed the protocol
- B. Analysis including all randomized patients regardless of treatment received
- C. Analysis including only patients with confirmed diagnosis
- D. Analysis excluding patients with protocol deviations

2. HER2 overexpression or amplification is clinically relevant in all of the following cancers EXCEPT:

- A. Breast cancer
- B. Gastric/gastroesophageal junction cancer
- C. NSCLC
- D. Pancreatic adenocarcinoma

3. Progression-free survival (PFS) is defined as:

- A. Time from randomization to disease progression or death, whichever comes first
- B. Time from first response to disease progression
- C. Time from treatment start to treatment discontinuation
- D. Time from randomization to the first metastatic event

Investigator & Site Recognition

Congratulations to all of the Investigators and the Northside Hospital and St. Joseph Candler Teams for their enrollment efforts for NCORP year 12! Their proactive patient screening processes and strong multidisciplinary collaboration have set a model for network excellence.

We also recognize ALL of our research nurses and data managers, whose dedication ensures protocol compliance and data integrity across all sites.

March Winners

Huge shoutout to our winner from last month's

Test Your Knowledge...

Elisha Curry (NGHS)

Way to go !

Who will be our winner this month?